Hikma Pharmaceuticals logo

HIK - Hikma Pharmaceuticals News Story

2650p 11.0  0.4%

Last Trade - 18/09/20

Sector
Healthcare
Size
Large Cap
Market Cap £6.11bn
Enterprise Value £6.50bn
Revenue £1.77bn
Position in Universe 133rd / 1807

BUZZ-Hikma eyes best day in 2 yrs on outlook boost, remdesivir production deal

Fri 7th August, 2020 10:16am
** Hikma Pharmaceuticals'  HIK.L  shares jump 11% to 2,396p,
making it the top gainer on London's FTSE 100  .FTSE 
    ** Co raises FY sales outlook for two big divisions after
higher first-half profit, as hospitals and distributors stocked
up on critical medicines during COVID-19 pandemic  urn:newsml:reuters.com:*:nL4N2F91ZX
    ** "We don't think a guidance upgrade was anticipated by the
market heading into results" - J.P.Morgan
    ** Stock on track for best day since March 2018
    ** Co also starts manufacturing remdesivir, an approved
treatment for COVID-19 from U.S.-based Gilead  GILD.O , for an
undisclosed amount at facility in Portugal  urn:newsml:reuters.com:*:nL4N2F92D1
    ** Shares have risen 20% so far this year

 (Reporting by Yadarisa Shabong in Bengaluru)
 ((yadarisa.shabong@thomsonreuters.com))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.